Overactive bladder (OAB) is defined by ICS (International Continence Society) as urgency, with or without urge incontinence, usually with frequency and nocturia. The pharmacological treatment was reduced to antimuscarinic. Recently, a new therapeutic class: beta 3-adrenoreceptor agonist is available in France, with encouraging results regarding its tolerance, main obstacle to good compliance regarding antimuscarinic treatment. However, further research is still needed to explore each subgroup as patient with lower urinary tract obstruction and neurological population. (C) 2016 Elsevier Masson SAS. All rights reserved.